Anca Askanase - Concepedia

Author

Anca Askanase

Also Known As

A Askanase, A D Askanase, A. Askanase, A. D. Askanase, A.D. Askanase, ANCA ASKANASE, ANCA D. ASKANASE, ANCA DINU ASKANASE, Alarcón, G S, Alarcón, Graciela S.

311

Publications

10.8K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Oklahoma Medical Research Foundation Feinstein Institute for Medical Research Medical University of South Carolina SUNY Downstate Health Sciences University

About

Anca Askanase is an author at Johns Hopkins University specializing in medicine, lupus, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	962
2	Public Health	4	4	487
3	Natural Sciences	1	1	26
4	Allergy	1	1	16
5	Biochemistry	1	1	26

Anca Askanase

101

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
Trial of Anifrolumab in Active Systemic Lupus Erythematosus Eric F. Morand, Richard Furie, Yoshiya Tanaka, New England Journal of Medicine	2019	1.2K
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus Michelle Petri, Mimi Kim, Kenneth Kalunian, New England Journal of Medicine	2005	1.1K
The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial Jill P. Buyon, Michelle Petri, Mimi Kim, Annals of Internal Medicine	2005	655
The frequency and outcome of lupus nephritis: results from an international inception cohort study John G. Hanly, Aidan G. O’Keeffe, Li Su, Lara D. Veeken	2015	605
2021 DORIS definition of remission in SLE: final recommendations from an international task force Ronald van Vollenhoven, George Βertsias, Andrea Doria, Lupus Science & Medicine	2021	299
Cancer risk in systemic lupus: An updated international multi-centre cohort study Sasha Bernatsky, Rosalind Ramsey‐Goldman, Jeremy A. Labrecque, Journal of Autoimmunity EpidemiologyCancer RiskCancer EpidemiologySystemic Lupus ErythematosusSystemic Lupus Erythematosus Treatment	2013	294
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE MA Dooley, Frédéric Houssiau, Cynthia Aranow, Lupus Renal ParametersDialysis TherapyNephrologyGlomerulonephritisRenal Function	2012	262
Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block Robert M. Clancy, Raj P. Kapur, Yair Molad, Arthritis & Rheumatism	2004	256
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine Peter Izmirly, Carolina Llanos, M. M. Guerra, Annals of the Rheumatic Diseases	2010	245
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis Yemil Atisha‐Fregoso, Susan Malkiel, Kristina M. Harris, Arthritis & Rheumatology	2020	197

Page 1